We are monitoring the impact of COVID-19 on Epilepsy Market Get in touch with us for detailed analysis Know More
Pulished Date October, 2020
ID: 10361
Share on
Share on

Global Epilepsy Market Size, Share, Trends, Growth Analysis Report - Segmented By Condition, Diagnosis & Treatment, End-User and Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa) - Industry Forecast (2020 to 2025)

Pulished: October, 2020
ID: 10361
Pages: 190

Epilepsy Market Size (2020 to 2025)

The global epilepsy market size is forecasted to grow at a CAGR of 9.12% between 2020 to 2025 and worth USD 2.54 billion by 2025.

Epilepsy is a disorder of the central nervous system that affects signaling between the nerves within the brain. The impairment in conduction can result in seizers and result in symptoms like abnormal sensations and loss of consciousness. The governments have now developed the healthcare system to a whole new level in the past 15 years, and this advancement in quality of healthcare will ensure that the disease is treated in the right way.

MARKET DRIVERS:

The primary factor driving the growth of the global epilepsy market is an increase in the geriatric population diagnosed with epilepsy worldwide during the forecast period. People with old age are more prone to epilepsy risk than young people, and thus the majority of cases are of older people. In 40% of cases, the cause of epilepsy is a brain injury. Advancements have positively influenced the global epilepsy market in epilepsy therapeutics as their efficiency is increased.

The rising government initiatives have resulted in more awareness among people and thus driven the growth of the market. The increased research and development by the entry of private players in this market have developed the products and market dynamics by identifying the demand and supply chain. Although the market is extremely crowded with branded and generic drugs, pharmaceutical companies have shifted their focus to developing safe adjunctive therapies for refractory patients.

MARKET RESTRAINTS:

The significant challenge for the market are the lack of healthcare facilities and the low quality of healthcare services in many countries around the world. Epilepsy is a disease related to the brain, requires complex procedures that can be made easy with better equipment, and lack of this equipment’s results in low success in brain surgeries. The lack of skilled healthcare professionals is also a major factor restraining the growth factor.

Impact of COVID-19 on the global epilepsy market: 

COVID-19 has negatively impacted the market. The prevalence of COVID-19 led to lockdown in the majority of areas around the world. It led to disruption in the supply chain of medical equipment and therapeutics required in treating epilepsy and thus negatively impacting the growth of the market. The emphasis by governments to improve their healthcare system due to the effects of a pandemic can have some positive impact on the market.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Covered

By Condition, Diagnosis & Treatment, End-User and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape and Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

 

This research report on the global epilepsy market has been segmented & sub-segmented based on condition, diagnosis, treatment, end-user, and region.

Epilepsy Market - By Condition:

  • Epilepsy drug-resistant / intractable epilepsy
  • Others

The other sub-segment had the largest market share in 2019, with around 70% market share, and is expected to grow at a reasonable rate during the forecast period. The development of the healthcare system and the development of therapeutics side of treatment is the main reason for the high growth of this segment. Increasing awareness will further drive the growth of the market.

The Epilepsy drug-resistant sub-segment had the second largest market share in 2019, with an expected growth rate to be relatively high during the forecast period. The emergence of rational polytherapy for treating disorders with almost no side effects will drive the growth of this sub-segment. The increase in the number of cases due to the rise in the geriatric population worldwide is a significant reason for this sub-segment to grow.

Epilepsy Market - By Diagnosis and Treatment:

  • Diagnosis
  • Treatment

Based on the diagnosis and treatment, the treatment sub-segment had the largest market share with a 66% share in the market with an expected positive rate during the forecast period. The growth rate projected for the forecast period is 6.81%. The treatment segment has been sub-segmented into anti-epileptic drugs, neurostimulation devices, brain surgery, ketogenic diet, etc. The main reason for the highest market share is the availability of affordable drugs for treating partial epileptic seizures. The approval of effective drugs by regulatory bodies is also an essential factor for market growth.

The diagnosis segment had the second largest market share in 2019 and is expected to grow fastest with a CAGR of 8.2% during the forecast period. The diagnosis segment has been further sub-segmented into imaging devices, blood tests, and others. The utilization of imaging tests and blood tests for the early diagnosis of the disease has driven the growth of this market. The imaging tests like CT Scan can reveal the abnormalities associated with the brain and thus can be proved very helpful.

Epilepsy Market - By End-User:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Diagnostic Centres
  • Others

Hospitals and Clinics had the largest market share of 35% in 2019 and is expected to grow at a reasonable rate during the forecast period. The development of healthcare facilities and the rising quality of healthcare infrastructure will further increase the growth rate. The increase in cases of epilepsy is also a significant contributing factor.

Clinics are expected to grow at the highest rate during the forecast period, with a 9.82% CAGR. Adoption of the latest equipment by doctors to provide excellent patient care can spur the growth of the segment. The increase in cases of epilepsy will help the market to grow at a reasonable rate.

Epilepsy Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North America region had the highest share of around 41% in 2019 in the global epilepsy market and is expected to grow at a reasonable rate during the forecast period. The increase in the geriatric population and improvement in the healthcare facility is the primary market growth driving factors.

Europe region had the second-largest market share with a healthy growth rate projection in the future. The advancement in technology and rising initiatives from the government Is the main reason for market growth.

Asia Pacific region is expected to grow with the highest growth rate during the forecast period. The increase in epilepsy cases due to the rise in population in countries like India and China is the main reason for the high market growth rate. Growing awareness and improved medical structure will also help the market to grow.

TOP COMPANIES IN THIS MARKET

Companies that are playing a dominating role in the global epilepsy market analyzed in this report are LivaNova, NeuroPace, GlaxoSmithKline PLC, Johnson and Johnson Services, Medtronic PLC, Eisai, GW Pharmaceuticals, UCB SA, Pfizer, Novartis AG, Takeda, Abbott Laboratories, Bausch Health, Sanofi and Sunovion Pharmaceuticals.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Report Overview
    1. Executive Summary
    2. Key Inferences
  4. Market Dynamics
    1. Impact Analysis
      1. Drivers
      2. Restraints
      3. Opportunities       
    2. Regulatory Environment
    3. Technology Timeline & Recent Trends
  5. Competitor Benchmarking Analysis
    1. Key Player Benchmarking                    
      1. Market share analysis      
      2. Products/Service
      3. Regional Presence               
    2. Mergers & Acquisition Landscape                     
    3. Joint Ventures & Collaborations
  6. MARKET SEGMENTATION
    1. By Condition
      1. Epilepsy drug-resistant / intractable epilepsy
      2. Others
      3. Y-o-Y Growth Analysis, By Condition
      4. Market Attractiveness Analysis, By Condition
      5. Market Share Analysis, By Condition
    2. By Diagnosis and Treatment
      1. Diagnosis
      2. Treatment
      3. Y-o-Y Growth Analysis, By Diagnosis and Treatment
      4. Market Attractiveness Analysis, By Diagnosis and Treatment
      5. Market Share Analysis, By Diagnosis and Treatment
    3. By End-users
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centres
      4. Diagnostic Centres
      5. Others
      6. Y-o-Y Growth Analysis, By End-User
      7. Market Attractiveness Analysis, By End-User
      8. Market Share Analysis, By End-User
  7. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. North America
      1. Introduction
      2. United States
      3. Canada
    3. Europe
      1. Introduction
      2. U.K
      3. Spain
      4. Germany
      5. Italy
      6. France
      7. Rest of Europe
    4. Asia-Pacific
      1. Introduction
      2. China
      3. India
      4. Japan
      5. South Korea
      6. Australia and NZ
      7. Rest of APAC
    5. Latin America
      1. Introduction
      2. Brazil
      3. Argentina
      4. Mexico
      5. Rest of Latin America
    6. Middle East & Africa
      1. Introduction
      2. Middle-East
      3. Africa
  8. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  9. MARKET LEADERS' ANALYSIS
    1. LivaNova
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. NeuroPace
    3. GlaxoSmithKline PLC
    4. Johnson and Johnson Services
    5. Medtronic PLC
    6. Eisai
    7. GW Pharmaceuticals
    8. UCB SA
    9. Pfizer
    10. Novartis AG
    11. Takeda
    12. Abbott Laboratories
    13. Bausch Health
    14. Sanofi
    15. Sunovion Pharmaceuticals.
  10. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, collaborations and Joint Ventures
    4. New Product Launches
  11. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  12. APPENDIX
  13. List of Tables
  14. List of Figures
  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of condition, diagnosis & treatment, and end-user along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Epilepsy Market, By Region, From 2020 to 2025 (USD Million)
  2. Global Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  3. Global Epilepsy drug-resistant / intractable epilepsy Market, By Region, From 2020 to 2025 (USD Million)
  4. Global Others Market, By Region, From 2020 to 2025 (USD Million)
  5. Global Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  6. Global Diagnosis Market, By Region, From 2020 to 2025 (USD Million)
  7. Global Treatment Market, By Region, From 2020 to 2025 (USD Million)
  8. Global Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  9. Global Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  10. Global Clinics Market, By Region, From 2020 to 2025 (USD Million)
  11. Global Ambulatory Surgical Centres Market, By Region, From 2020 to 2025 (USD Million)
  12. Global Diagnostic Centres Market, By Region, From 2020 to 2025 (USD Million)
  13. Global Others Market, By Region, From 2020 to 2025 (USD Million)
  14. North America Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  15. North America Epilepsy drug-resistant / intractable epilepsy Market, By Region, From 2020 to 2025 (USD Million)
  16. North America Others Market, By Region, From 2020 to 2025 (USD Million)
  17. North America Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  18. North America Diagnosis Market, By Region, From 2020 to 2025 (USD Million)
  19. North America Treatment Market, By Region, From 2020 to 2025 (USD Million)
  20. North America Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  21. North America Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  22. North America Clinics Market, By Region, From 2020 to 2025 (USD Million)
  23. North America Ambulatory Surgical Centres Market, By Region, From 2020 to 2025 (USD Million)
  24. North America Diagnostic Centres Market, By Region, From 2020 to 2025 (USD Million)
  25. North America Others Market, By Region, From 2020 to 2025 (USD Million)
  26. United States Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  27. United States Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  28. United States Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  29. Canada Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  30. Canada Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  31. Canada Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  32. Europe Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  33. Europe Epilepsy drug-resistant / intractable epilepsy Market, By Region, From 2020 to 2025 (USD Million)
  34. Europe Others Market, By Region, From 2020 to 2025 (USD Million)
  35. Europe Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  36. Europe Diagnosis Market, By Region, From 2020 to 2025 (USD Million)
  37. Europe Treatment Market, By Region, From 2020 to 2025 (USD Million)
  38. Europe Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  39. Europe Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  40. Europe Clinics Market, By Region, From 2020 to 2025 (USD Million)
  41. Europe Ambulatory Surgical Centres Market, By Region, From 2020 to 2025 (USD Million)
  42. Europe Diagnostic Centres Market, By Region, From 2020 to 2025 (USD Million)
  43. Europe Others Market, By Region, From 2020 to 2025 (USD Million)
  44. U.K. Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  45. U.K. Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  46. U.K. Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  47. Germany Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  48. Germany Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  49. Germany Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  50. France Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  51. France Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  52. France Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  53. Italy Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  54. Italy Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  55. Italy Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  56. Spain Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  57. Spain Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  58. Spain Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  59. Asia Pacific Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  60. Asia Pacific Epilepsy drug-resistant / intractable epilepsy Market, By Region, From 2020 to 2025 (USD Million)
  61. Asia Pacific Others Market, By Region, From 2020 to 2025 (USD Million)
  62. Asia Pacific Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  63. Asia Pacific Diagnosis Market, By Region, From 2020 to 2025 (USD Million)
  64. Asia Pacific Treatment Market, By Region, From 2020 to 2025 (USD Million)
  65. Asia Pacific Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  66. Asia Pacific Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  67. Asia Pacific Clinics Market, By Region, From 2020 to 2025 (USD Million)
  68. Asia Pacific Ambulatory Surgical Centres Market, By Region, From 2020 to 2025 (USD Million)
  69. Asia Pacific Diagnostic Centres Market, By Region, From 2020 to 2025 (USD Million)
  70. Asia Pacific Others Market, By Region, From 2020 to 2025 (USD Million)
  71. Japan Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  72. Japan Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  73. Japan Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  74. China Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  75. China Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  76. China Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  77. India Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  78. India Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  79. India Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  80. Australia Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  81. Australia Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  82. Australia Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  83. South Korea Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  84. South Korea Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  85. South Korea Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  86. Latin America Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  87. Latin America Epilepsy drug-resistant / intractable epilepsy Market, By Region, From 2020 to 2025 (USD Million)
  88. Latin America Others Market, By Region, From 2020 to 2025 (USD Million)
  89. Latin America Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  90. Latin America Diagnosis Market, By Region, From 2020 to 2025 (USD Million)
  91. Latin America Treatment Market, By Region, From 2020 to 2025 (USD Million)
  92. Latin America Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  93. Latin America Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  94. Latin America Clinics Market, By Region, From 2020 to 2025 (USD Million)
  95. Latin America Ambulatory Surgical Centres Market, By Region, From 2020 to 2025 (USD Million)
  96. Latin America Diagnostic Centres Market, By Region, From 2020 to 2025 (USD Million)
  97. Latin America Others Market, By Region, From 2020 to 2025 (USD Million)
  98. Brazil Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  99. Brazil Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  100. Brazil Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  101. Argentina Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  102. Argentina Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  103. Argentina Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  104. Mexico Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  105. Mexico Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  106. Mexico Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  107. Rest of Latin America Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  108. Rest of Latin America Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  109. Rest of Latin America Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  110. Middle East and Africa Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  111. Middle East and Africa Epilepsy drug-resistant / intractable epilepsy Market, By Region, From 2020 to 2025 (USD Million)
  112. Middle East and Africa Others Market, By Region, From 2020 to 2025 (USD Million)
  113. Middle East and Africa Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  114. Middle East and Africa Diagnosis Market, By Region, From 2020 to 2025 (USD Million)
  115. Middle East and Africa Treatment Market, By Region, From 2020 to 2025 (USD Million)
  116. Middle East and Africa Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  117. Middle East and Africa Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  118. Middle East and Africa Clinics Market, By Region, From 2020 to 2025 (USD Million)
  119. Middle East and Africa Ambulatory Surgical Centres Market, By Region, From 2020 to 2025 (USD Million)
  120. Middle East and Africa Diagnostic Centres Market, By Region, From 2020 to 2025 (USD Million)
  121. Middle East and Africa Others Market, By Region, From 2020 to 2025 (USD Million)
  122. Middle East Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  123. Middle East Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  124. Middle East Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)
  125. Africa Epilepsy Market, By Condition, From 2020 to 2025 (USD Million)
  126. Africa Epilepsy Market, By Diagnosis and Treatment, From 2020 to 2025 (USD Million)
  127. Africa Epilepsy Market, By End-User, From 2020 to 2025 (USD Million)

 

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample